/CODX
CODX Stock - Co-Diagnostics, Inc.
Healthcare|Medical - DevicesNASDAQ
$2.76-53.85%
$3.22 (-53.85%) • Jan 13
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+226.1%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CODX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.73 – $2.79
TARGET (TP)$9.00
STOP LOSS$2.54
RISK/REWARD1:28.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.26
52W High$46.50
52W Low$2.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.92M | $6.81M | $34.22M | $97.89M | $74.55M |
| Gross Profit | $2.92M | $2.63M | $28.74M | $86.31M | $57.96M |
| Gross Margin | 74.5% | 38.6% | 84.0% | 88.2% | 77.7% |
| Operating Income | $-40,081,310 | $-42,706,234 | $-26,979,837 | $46.06M | $41.69M |
| Net Income | $-37,639,008 | $-35,332,865 | $-14,238,249 | $36.66M | $42.48M |
| Net Margin | -961.4% | -518.7% | -41.6% | 37.5% | 57.0% |
| EPS | $-37.20 | $-36.00 | $-13.57 | $38.10 | $1.59 |
Company Overview
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
1
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish1 Neutral/Bearish
Price Targets
$5
Average Target
↑ 81.2% Upside
Now
$5
Low
$5
Average
$5
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 12th 2022 | Sidoti | Downgrade | Neutral | $5 |
Earnings History & Surprises
CODXBeat Rate
68%
Last 19 quarters
Avg Surprise
-4.7%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-4.80
Q4 2025
EPS Surprise History
Q1 24
-150.0%
$-0.50vs$-0.20
Q2 24
-47.6%
$-0.31vs$-0.21
Q3 24
+26.5%
$-0.25vs$-0.34
Q4 24
+3.0%
$-0.32vs$-0.33
Q1 25
-5.9%
$-0.36vs$-0.34
Q2 25
+27.3%
$-0.24vs$-0.33
Q3 25
+8.0%
$-0.23vs$-0.25
Q4 25
+15.9%
$-4.80vs$-5.71
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-3.90 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-5.71 | $-4.80 | +15.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.33 | $-0.24 | +27.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.33 | $-0.32 | +3.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.21 | $-0.31 | -47.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.20 | $-0.50 | -150.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.29 | $-0.20 | +31.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.24 | $-0.31 | -29.2% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.15 | $-0.32 | -113.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $0.15 | $-0.10 | -166.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $0.18 | $0.26 | +44.4% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $0.15 | $0.25 | +66.7% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $0.21 | $0.38 | +81.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $0.23 | $0.33 | +43.5% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $0.20 | $0.26 | +30.0% | ✓ BEAT |
Latest News
Co-Diagnostics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -40.47%
📉 NegativeBenzinga•Jan 13, 2026, 05:40 PM
Co-Diagnostics shares are trading lower after the company announced it will be delisted from the Nasdaq.
📉 NegativeBenzinga•Jan 13, 2026, 05:29 PM
Co-Diagnostics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -12.21%
📉 NegativeBenzinga•Jan 13, 2026, 05:27 PM
Co-Diagnostics To Be Delisted From Nasdaq Effective Jan 14, 2026, After Failing Minimum $1.00 Bid Price Rule; Plans Hearing While Trading Moves To OTC Pink
📉 NegativeBenzinga•Jan 13, 2026, 05:27 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Jan 1, 2026, 12:50 AM
Co-Diagnostics To Implement 1-For-30 Reverse Stock Split, Effective January 2, 2026
📉 NegativeBenzinga•Dec 30, 2025, 02:02 PM
Co-Diagnostics Granted Australian Patent Covering Co-Dx PCR Platform Technologies
📈 PositiveBenzinga•Dec 29, 2025, 02:02 PM
Co-Diagnostics Says Co Performs Analysis Of Influenza Co-Primers To Confirm Reactivity Against Flu A H3N2 Mutation
➖ NeutralBenzinga•Dec 17, 2025, 02:01 PM
HC Wainwright & Co. Reiterates Neutral on Co-Diagnosticsto Neutral
➖ NeutralBenzinga•Nov 24, 2025, 12:31 PM
Co-Diagnostics Initiates Clinical Evaluations for Its Co-Dx PCR Flu A/B, COVID-19, RSV Test Kit
📈 PositiveBenzinga•Nov 18, 2025, 02:04 PM
Co-Diagnostics Q3 EPS $(0.16) Beats $(0.17) Estimate, Sales $145.380K Miss $150.000K Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:02 PM
Co-Diagnostics Engages Maxim Group To Explore Strategic Options For Indian Joint Venture CoSara, Including Potential SPAC Merger
📈 PositiveBenzinga•Nov 5, 2025, 02:08 PM
Co-Diagnostics Forms New Artificial Intelligence Business Unit To Integrate Its Current, Planned AI Applications Into Co-Dx Primer Ai
📈 PositiveBenzinga•Nov 3, 2025, 02:18 PM
Co-Diagnostics Files For Offering 12M Shares Of Common Stock And 725,000 Pre-Funded Warrants
📉 NegativeBenzinga•Oct 28, 2025, 09:45 PM
Co-Diagnostics shares are trading lower after the company announced a $7 million registered direct offering of 12,727,272 shares at $0.55 per share.
📉 NegativeBenzinga•Oct 28, 2025, 03:59 PM
Co-Diagnostics Announces $7M Registered Direct Offering Of 12,727,272 Shares At A Price Of $0.55/Share
📉 NegativeBenzinga•Oct 28, 2025, 01:35 PM
D. Boral Capital Maintains Buy on Co-Diagnostics, Maintains $3 Price Target
📈 PositiveBenzinga•Oct 28, 2025, 11:09 AM
Co-Diagnostics Shares Resume Trade
➖ NeutralBenzinga•Oct 27, 2025, 06:26 PM
Co-Diagnostics shares are trading higher after the company signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics and localize its Co-Dx PCR platform across the Middle East.
📈 PositiveBenzinga•Oct 27, 2025, 12:47 PM
EXCLUSIVE: Co-Diagnostics Tells Benzinga 'The new Saudi-based CoMira Diagnostics joint venture will be engaged in manufacturing and distribution of the Company's upcoming Co-Dx PCR platform and other Co-Dx IP across KSA and 18 other MENA countries'
📈 PositiveBenzinga•Oct 27, 2025, 12:30 PM
Frequently Asked Questions about CODX
What is CODX's current stock price?
Co-Diagnostics, Inc. (CODX) is currently trading at $2.76 per share. The stock has moved -53.85% today.
What is the analyst price target for CODX?
The average analyst price target for CODX is $9.00, based on 1 analyst.
What sector is Co-Diagnostics, Inc. in?
Co-Diagnostics, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is CODX's market cap?
Co-Diagnostics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CODX pay dividends?
No, Co-Diagnostics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADGM
Adagio Medical Holdings, Inc.
$0.91
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.60
Mkt Cap: $0.0B
ALUR
Allurion Technologies Inc.
$1.73
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$2.70
Mkt Cap: $0.0B
NVNO
enVVeno Medical Corporation
$0.34
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.19
Mkt Cap: $0.0B
SINT
Sintx Technologies, Inc.
$3.78
Mkt Cap: $0.0B
TNON
Tenon Medical, Inc.
$0.97
Mkt Cap: $0.0B
VVOS
Vivos Therapeutics, Inc.
$2.00
Mkt Cap: $0.0B
XAIR
Beyond Air, Inc.
$2.44
Mkt Cap: $0.0B
Explore stocks similar to CODX for comparison